MO850: Casirivimab/Imdevimab in Vaccinated Chronic Haemodialyzed Patients With Acute Mild Covid-19: Safety And Efficiency
| Autor: | Matthieu Monge, Soledad Henriquez, Caroline Humbert, Elsa Guiard, Mahmoud Allouache, Jean-Marc Yhuel, Marie Lavollay, Clemence Richaud, Afsaneh Gohari |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Nephrology Dialysis Transplantation. 37 |
| ISSN: | 1460-2385 0931-0509 |
| DOI: | 10.1093/ndt/gfac083.032 |
| Popis: | BACKGROUND AND AIMS Casirivimab/imdevimab (C/I) is a combination of two neutralizing human monoclonal antibodies against the SARS-CoV-2. It has been approved for primary prophylaxis or acute SARS-CoV-2 infection in patients with a poor vaccine response. Chronic haemodialyzed (CHD) patients are a high-risk population for both severe COVID-19 and impaired vaccine response. We herein report the safety and efficiency of C/I in CHD patients with acute mild COVID-19. METHOD In a single-centre haemodialysis facility, all 56 CHD patients received 3 injections of anti-COVID-19 mRNA BNT162b2 vaccine, with anti-S protein antibodies response assessed 7 months after the last injection. During follow-up, patients who presented an acute mild SARS-CoV-2 infection without the need for oxygen therapy and a poor vaccine response received within 5 days after diagnosis 600mg/600mg of C/I. The combination of monoclonal antibodies was infused only once after the end of the dialysis session during 20 min. Patients were kept under surveillance during 1 h before discharge. Efficiency was assessed by RT-PCR 7 days after C/I infusion and clinical evaluation. RESULTS Six CHD patients had an acute COVID-19 without oxygen therapy requirement and four had a vaccine response CONCLUSION 600 mg/600 mg of C/I is a safe and efficient treatment for CHD patients with a poor vaccine humoral response presenting mild acute Delta variant COVID-19 without oxygen requirement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|